Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-365 pembrolizumab combination therapies in metastatic castration-resistant prostate cancer
NL-OMON52154Phase 2Recruiting
- Sponsor
- Farmaceutische Industrie
- Start
- May 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib, belzutifan, vibostolimab, olaparib in metastatic castration-resistant prostate cancer (mCRPC), neuroendocrine prostate cancer (NEPC), sponsored by Farmaceutische Industrie. Started May 2022; status: recruiting.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)neuroendocrine prostate cancer (NEPC)
Beyond the preview
Go deeper on NL-OMON52154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52154.